<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35493458</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>03</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>03</Day>
      </DateRevised>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Electronic">1664-3224</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>13</Volume>
            <PubDate>
              <Year>2022</Year>
            </PubDate>
          </JournalIssue>
          <Title>Frontiers in immunology</Title>
          <ISOAbbreviation>Front Immunol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Intranasal Immunization With a c-di-GMP-Adjuvanted Acellular Pertussis Vaccine Provides Superior Immunity Against <i>Bordetella pertussis</i> in a Mouse Model.</ArticleTitle>
        <Pagination>
          <StartPage>878832</StartPage>
          <MedlinePgn>878832</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">878832</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2022.878832</ELocationID>
        <Abstract>
          <AbstractText>Pertussis, caused by the gram-negative bacterium <i>Bordetella pertussis</i>, is a highly contagious respiratory disease. Intranasal vaccination is an ideal strategy to prevent pertussis, as the nasal mucosa represents the first-line barrier to <i>B. pertussis</i> infection. The current intramuscular acellular pertussis (aP) vaccines elicit strong antibody and Th2-biased responses but not necessary cellular and mucosal immunity. Here, we formulated two cyclic dinucleotide (CDN)-adjuvanted aP subunit vaccines, a mammalian 2',3'-cGAMP-adjuvanted aP vaccine and a bacterial-derived c-di-GMP-adjuvanted aP vaccine, and evaluated their immunogenicity in a mouse model. We found that the aP vaccine alone delivered intranasally (IN) induced moderate systemic and mucosal humoral immunity but weak cellular immunity, whereas the alum-adjuvanted aP vaccine administered intraperitoneally elicited higher Th2 and systemic humoral immune responses but weaker Th1 and Th17 and mucosal immune responses. In contrast, both CDN-adjuvanted aP vaccines administered <i>via</i> the IN route induced robust humoral and cellular immunity systemically and mucosally. Furthermore, the c-di-GMP-adjuvanted aP vaccine generated better antibody production and stronger Th1 and Th17 responses than the 2',3'-cGAMP-adjuvanted aP vaccine. In addition, following <i>B. pertussis</i> challenge, the group of mice that received IN immunization with the c-di-GMP-adjuvanted aP vaccine showed better protection than all other groups of vaccinated mice, with decreased inflammatory cell infiltration in the lung and reduced bacterial burden in both the upper and lower respiratory tracts. In summary, the c-di-GMP-adjuvanted aP vaccine can elicit a multifaceted potent immune response resulting in robust bacterial clearance in the respiratory tract, which indicates that c-di-GMP can serve as a potential mucosal adjuvant for the pertussis vaccine.</AbstractText>
          <CopyrightInformation>Copyright © 2022 Jiang, Wang, Su, Cai, Li, Liang, Gu, Sun and Shi.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Jiang</LastName>
            <ForeName>Wenwen</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Yunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Diseases, Institute of Medical Biology, Chinese Academy of Medical Science &amp; Peking Union Medical College, Kunming, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Xiaoyu</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Yunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Diseases, Institute of Medical Biology, Chinese Academy of Medical Science &amp; Peking Union Medical College, Kunming, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Su</LastName>
            <ForeName>Yuhao</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Immunogenetics, Institute of Medical Biology, Chinese Academy of Medical Science &amp; Peking Union Medical College, Kunming, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cai</LastName>
            <ForeName>Lukui</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Vaccine Development, Institute of Medical Biology, Chinese Academy of Medical Science &amp; Peking Union Medical College, Kunming, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Jingyan</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Vaccine Development, Institute of Medical Biology, Chinese Academy of Medical Science &amp; Peking Union Medical College, Kunming, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liang</LastName>
            <ForeName>Jiangli</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Yunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Diseases, Institute of Medical Biology, Chinese Academy of Medical Science &amp; Peking Union Medical College, Kunming, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gu</LastName>
            <ForeName>Qin</ForeName>
            <Initials>Q</Initials>
            <AffiliationInfo>
              <Affiliation>Yunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Diseases, Institute of Medical Biology, Chinese Academy of Medical Science &amp; Peking Union Medical College, Kunming, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sun</LastName>
            <ForeName>Mingbo</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Yunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Diseases, Institute of Medical Biology, Chinese Academy of Medical Science &amp; Peking Union Medical College, Kunming, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Laboratory of Vaccine Development, Institute of Medical Biology, Chinese Academy of Medical Science &amp; Peking Union Medical College, Kunming, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shi</LastName>
            <ForeName>Li</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Immunogenetics, Institute of Medical Biology, Chinese Academy of Medical Science &amp; Peking Union Medical College, Kunming, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>04</Month>
          <Day>13</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Front Immunol</MedlineTA>
        <NlmUniqueID>101560960</NlmUniqueID>
        <ISSNLinking>1664-3224</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000276">Adjuvants, Immunologic</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010567">Pertussis Vaccine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>61093-23-0</RegistryNumber>
          <NameOfSubstance UI="C062025">bis(3',5')-cyclic diguanylic acid</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>H2D2X058MU</RegistryNumber>
          <NameOfSubstance UI="D006152">Cyclic GMP</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000276" MajorTopicYN="N">Adjuvants, Immunologic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001886" MajorTopicYN="Y">Bordetella pertussis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006152" MajorTopicYN="N">Cyclic GMP</DescriptorName>
          <QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007114" MajorTopicYN="N">Immunization</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008322" MajorTopicYN="N">Mammals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010567" MajorTopicYN="N">Pertussis Vaccine</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014917" MajorTopicYN="Y">Whooping Cough</DescriptorName>
          <QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">2’,3’-cGAMP</Keyword>
        <Keyword MajorTopicYN="N">Bordetella pertussis</Keyword>
        <Keyword MajorTopicYN="N">acellular pertussis vaccine (aP)</Keyword>
        <Keyword MajorTopicYN="N">c-di-GMP</Keyword>
        <Keyword MajorTopicYN="N">cyclic dinucleotides (CDNs)</Keyword>
        <Keyword MajorTopicYN="N">mucosal immunity</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>18</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>22</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>2</Day>
          <Hour>6</Hour>
          <Minute>20</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>3</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>4</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35493458</ArticleId>
        <ArticleId IdType="pmc">PMC9043693</ArticleId>
        <ArticleId IdType="doi">10.3389/fimmu.2022.878832</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>
Herzog C. Changing From Whole-Cell to Acellular Pertussis Vaccines Would Trade Superior Tolerability for Inferior Protection. Expert Rev Vaccines (2015) 14:1065–72. doi: 10.1586/14760584.2015.1059759
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1586/14760584.2015.1059759</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Patterson J, Kagina BM, Gold M, Hussey GD, Muloiwa R. Comparison of Adverse Events Following Immunisation With Acellular and Whole-Cell Pertussis Vaccines: A Systematic Review. Vaccine (2018) 36:6007–16. doi: 10.1016/j.vaccine.2018.08.022
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.vaccine.2018.08.022</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Barkoff AM, Mertsola J, Pierard D, Dalby T, Hoegh SV, Guillot S, et al. . Pertactin-Deficient Bordetella Pertussis Isolates: Evidence of Increased Circulation in Europe, 1998 to 2015. Euro Surveill (2019) 24:1700832. doi: 10.2807/1560-7917.Es.2019.24.7.1700832
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2807/1560-7917.Es.2019.24.7.1700832</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Bouchez V, Guillot S, Landier A, Armatys N, Matczak S, Toubiana J, et al. . Evolution of Bordetella Pertussis Over a 23-Year Period in France, 1996 to 2018. Euro Surveill (2021) 26:2001213. doi: 10.2807/1560-7917.Es.2021.26.37.2001213
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2807/1560-7917.Es.2021.26.37.2001213</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Klein NP, Bartlett J, Rowhani-Rahbar A, Fireman B, Baxter R. Waning Protection After Fifth Dose of Acellular Pertussis Vaccine in Children. N Engl J Med (2012) 367:1012–9. doi: 10.1056/NEJMoa1200850
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1200850</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Klein NP, Bartlett J, Fireman B, Rowhani-Rahbar A, Baxter R. Comparative Effectiveness of Acellular Versus Whole-Cell Pertussis Vaccines in Teenagers. Pediatrics (2013) 131:e1716–22. doi: 10.1542/peds.2012-3836
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1542/peds.2012-3836</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Althouse BM, Scarpino SV. Asymptomatic Transmission and the Resurgence of Bordetella Pertussis. BMC Med (2015) 13:146. doi: 10.1186/s12916-015-0382-8
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12916-015-0382-8</ArticleId>
            <ArticleId IdType="pmc">PMC4482312</ArticleId>
            <ArticleId IdType="pubmed">26103968</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Warfel JM, Zimmerman LI, Merkel TJ. Acellular Pertussis Vaccines Protect Against Disease But Fail to Prevent Infection and Transmission in a Nonhuman Primate Model. Proc Natl Acad Sci USA (2014) 111:787–92. doi: 10.1073/pnas.1314688110
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1314688110</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Craig R, Kunkel E, Crowcroft NS, Fitzpatrick MC, de Melker H, Althouse BM, et al. . Asymptomatic Infection and Transmission of Pertussis in Households: A Systematic Review. Clin Infect Dis (2020) 70:152–61. doi: 10.1093/cid/ciz531
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/cid/ciz531</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Gill CJ, Gunning CE, MacLeod WB, Mwananyanda L, Thea DM, Pieciak RC, et al. . Asymptomatic Bordetella Pertussis Infections in a Longitudinal Cohort of Young African Infants and Their Mothers. Elife (2021) 10:e65663. doi: 10.7554/eLife.65663
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7554/eLife.65663</ArticleId>
            <ArticleId IdType="pmc">PMC8184211</ArticleId>
            <ArticleId IdType="pubmed">34097599</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Romagnani S. Th1/Th2 Cells. Inflamm Bowel Dis (1999) 5:285–94. doi: 10.1097/00054725-199911000-00009
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/00054725-199911000-00009</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Solans L, Locht C. The Role of Mucosal Immunity in Pertussis. Front Immunol (2019) 9:3068. doi: 10.3389/fimmu.2018.03068
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2018.03068</ArticleId>
            <ArticleId IdType="pmc">PMC6339907</ArticleId>
            <ArticleId IdType="pubmed">30692990</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Warfel JM, Merkel TJ. Bordetella Pertussis Infection Induces a Mucosal IL-17 Response and Long-Lived Th17 and Th1 Immune Memory Cells in Nonhuman Primates. Mucosal Immunol (2013) 6:787–96. doi: 10.1038/mi.2012.117
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/mi.2012.117</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Allen AC, Wilk MM, Misiak A, Borkner L, Murphy D, Mills KHG. Sustained Protective Immunity Against Bordetella Pertussis Nasal Colonization by Intranasal Immunization With a Vaccine-Adjuvant Combination That Induces IL-17-Secreting T(RM) Cells. Mucosal Immunol (2018) 11:1763–76. doi: 10.1038/s41385-018-0080-x
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41385-018-0080-x</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Boehm DT, Wolf MA, Hall JM, Wong TY, Sen-Kilic E, Basinger HD, et al. . Intranasal Acellular Pertussis Vaccine Provides Mucosal Immunity and Protects Mice From Bordetella Pertussis. NPJ Vaccines (2019) 4:40. doi: 10.1038/s41541-019-0136-2
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41541-019-0136-2</ArticleId>
            <ArticleId IdType="pmc">PMC6776550</ArticleId>
            <ArticleId IdType="pubmed">31602318</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Hall JM, Bitzer GJ, DeJong MA, Kang J, Wong TY, Wolf MA, et al. . Mucosal Immunization With DTaP Confers Protection Against Bordetella Pertussis Infection and Cough in Sprague-Dawley Rats. Infect Immun (2021) 89(12):e0034621. doi: 10.1128/iai.00346-21
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/iai.00346-21</ArticleId>
            <ArticleId IdType="pmc">PMC8594602</ArticleId>
            <ArticleId IdType="pubmed">34516235</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Yan H, Chen W. The Promise and Challenges of Cyclic Dinucleotides as Molecular Adjuvants for Vaccine Development. Vaccines (Basel) (2021) 9:917. doi: 10.3390/vaccines9080917
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/vaccines9080917</ArticleId>
            <ArticleId IdType="pmc">PMC8402453</ArticleId>
            <ArticleId IdType="pubmed">34452042</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Chen W, Kuolee R, Yan H. The Potential of 3’,5’-Cyclic Diguanylic Acid (C-Di-GMP) as an Effective Vaccine Adjuvant. Vaccine (2010) 28:3080–5. doi: 10.1016/j.vaccine.2010.02.081
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.vaccine.2010.02.081</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ebensen T, Debarry J, Pedersen GK, Blazejewska P, Weissmann S, Schulze K, et al. . Mucosal Administration of Cycle-Di-Nucleotide-Adjuvanted Virosomes Efficiently Induces Protection Against Influenza H5N1 in Mice. Front Immunol (2017) 8:1223. doi: 10.3389/fimmu.2017.01223
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2017.01223</ArticleId>
            <ArticleId IdType="pmc">PMC5624999</ArticleId>
            <ArticleId IdType="pubmed">29033942</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Martin TL, Jee J, Kim E, Steiner HE, Cormet-Boyaka E, Boyaka PN. Sublingual Targeting of STING With 3’3’-cGAMP Promotes Systemic and Mucosal Immunity Against Anthrax Toxins. Vaccine (2017) 35:2511–9. doi: 10.1016/j.vaccine.2017.02.064
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.vaccine.2017.02.064</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Luo J, Liu X-P, Xiong F-F, Gao F-X, Yi Y-L, Zhang M, et al. . Enhancing Immune Response and Heterosubtypic Protection Ability of Inactivated H7N9 Vaccine by Using STING Agonist as a Mucosal Adjuvant. Front Immunol (2019) 10:2274. doi: 10.3389/fimmu.2019.02274
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2019.02274</ArticleId>
            <ArticleId IdType="pmc">PMC6777483</ArticleId>
            <ArticleId IdType="pubmed">31611875</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Danilchanka O, Mekalanos JJ. Cyclic Dinucleotides and the Innate Immune Response. Cell (2013) 154:962–70. doi: 10.1016/j.cell.2013.08.014
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2013.08.014</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ross P, Weinhouse H, Aloni Y, Michaeli D, Weinberger-Ohana P, Mayer R, et al. . Regulation of Cellulose Synthesis in Acetobacter Xylinum by Cyclic Diguanylic Acid. Nature (1987) 325:279–81. doi: 10.1038/325279a0
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/325279a0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Römling U, Galperin MY, Gomelsky M. Cyclic Di-GMP: The First 25 Years of a Universal Bacterial Second Messenger. Microbiol Mol Biol Rev (2013) 77:1–52. doi: 10.1128/mmbr.00043-12
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/mmbr.00043-12</ArticleId>
            <ArticleId IdType="pmc">PMC3591986</ArticleId>
            <ArticleId IdType="pubmed">23471616</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Karaolis DK, Cheng K, Lipsky M, Elnabawi A, Catalano J, Hyodo M, et al. . 3’,5’-Cyclic Diguanylic Acid (C-Di-GMP) Inhibits Basal and Growth Factor-Stimulated Human Colon Cancer Cell Proliferation. Biochem Biophys Res Commun (2005) 329:40–5. doi: 10.1016/j.bbrc.2005.01.093
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbrc.2005.01.093</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Sun L, Wu J, Du F, Chen X, Chen ZJ. Cyclic GMP-AMP Synthase is a Cytosolic DNA Sensor That Activates the Type I Interferon Pathway. Science (2013) 339:786–91. doi: 10.1126/science.1232458
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.1232458</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Zhang X, Shi H, Wu J, Zhang X, Sun L, Chen C, et al. . Cyclic GMP-AMP Containing Mixed Phosphodiester Linkages is an Endogenous High-Affinity Ligand for STING. Mol Cell (2013) 51:226–35. doi: 10.1016/j.molcel.2013.05.022
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.molcel.2013.05.022</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Su M, Zheng J, Gan L, Zhao Y, Fu Y, Chen Q. Second Messenger 2’3’-Cyclic GMP-AMP (2’3’-cGAMP):Synthesis, Transmission, and Degradation. Biochem Pharmacol (2022) 198:114934. doi: 10.1016/j.bcp.2022.114934
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bcp.2022.114934</ArticleId>
            <ArticleId IdType="pubmed">35104477</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Morehouse BR, Govande AA, Millman A, Keszei AFA, Lowey B, Ofir G, et al. . STING Cyclic Dinucleotide Sensing Originated in Bacteria. Nature (2020) 586:429–33. doi: 10.1038/s41586-020-2719-5
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41586-020-2719-5</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kamachi K, Toyoizumi-Ajisaka H, Toda K, Soeung SC, Sarath S, Nareth Y, et al. . Development and Evaluation of a Loop-Mediated Isothermal Amplification Method for Rapid Diagnosis of Bordetella Pertussis Infection. J Clin Microbiol (2006) 44:1899–902. doi: 10.1128/jcm.44.5.1899-1902.2006
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/jcm.44.5.1899-1902.2006</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Jiang W, Shi L, Cai L, Wang X, Li J, Li H, et al. . A Two-Adjuvant Multiantigen Candidate Vaccine Induces Superior Protective Immune Responses Against SARS-CoV-2 Challenge. Cell Rep (2021) 37:110112. doi: 10.1016/j.celrep.2021.110112
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.celrep.2021.110112</ArticleId>
            <ArticleId IdType="pmc">PMC8610932</ArticleId>
            <ArticleId IdType="pubmed">34863353</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Sun M, Ma Y, Xu Y, Yang H, Shi L, Che Y, et al. . Dynamic Profiles of Neutralizing Antibody Responses Elicited in Rhesus Monkeys Immunized With a Combined Tetravalent DTaP-Sabin IPV Candidate Vaccine. Vaccine (2014) 32:1100–6. doi: 10.1016/j.vaccine.2013.12.025
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.vaccine.2013.12.025</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Raeven RHM, Rockx-Brouwer D, Kanojia G, van der Maas L, Bindels THE, Ten Have R, et al. . Intranasal Immunization With Outer Membrane Vesicle Pertussis Vaccine Confers Broad Protection Through Mucosal IgA and Th17 Responses. Sci Rep (2020) 10:7396–. doi: 10.1038/s41598-020-63998-2
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41598-020-63998-2</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Romagnani S. T-Cell Subsets (Th1 Versus Th2). Ann Allergy Asthma Immunol (2000) 85:9–21. doi: 10.1016/S1081-1206(10)62426-X
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1081-1206(10)62426-X</ArticleId>
            <ArticleId IdType="pubmed">10923599</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Cock PJ, Fields CJ, Goto N, Heuer ML, Rice PM. The Sanger FASTQ File Format for Sequences With Quality Scores, and the Solexa/Illumina FASTQ Variants. Nucleic Acids Res (2010) 38:1767–71. doi: 10.1093/nar/gkp1137
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/nar/gkp1137</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kim D, Langmead B, Salzberg SL. HISAT: A Fast Spliced Aligner With Low Memory Requirements. Nat Methods (2015) 12:357–60. doi: 10.1038/nmeth.3317
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nmeth.3317</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Love MI, Huber W, Anders S. Moderated Estimation of Fold Change and Dispersion for RNA-Seq Data With Deseq2. Genome Biol (2014) 15:550. doi: 10.1186/s13059-014-0550-8
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13059-014-0550-8</ArticleId>
            <ArticleId IdType="pmc">PMC4302049</ArticleId>
            <ArticleId IdType="pubmed">25516281</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Jiang W, Wei C, Mou D, Zuo W, Liang J, Ma X, et al. . Infant Rhesus Macaques as a non-Human Primate Model of Bordetella Pertussis Infection. BMC Infect Dis (2021) 21:407. doi: 10.1186/s12879-021-06090-y
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12879-021-06090-y</ArticleId>
            <ArticleId IdType="pmc">PMC8091708</ArticleId>
            <ArticleId IdType="pubmed">33941094</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Libanova R, Ebensen T, Schulze K, Bruhn D, Nörder M, Yevsa T, et al. . The Member of the Cyclic Di-Nucleotide Family Bis-(3’, 5’)-Cyclic Dimeric Inosine Monophosphate Exerts Potent Activity as Mucosal Adjuvant. Vaccine (2010) 28:2249–58. doi: 10.1016/j.vaccine.2009.12.045
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.vaccine.2009.12.045</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Zhao T, Mo Z, Ying Z, Huang T, Che Y, Li G, et al. . Post Hoc Analysis of Two Clinical Trials to Compare the Immunogenicity and Safety of Different Polio Immunization Schedules in Chinese Infants. Ann Transl Med (2021) 9:253. doi: 10.21037/atm-20-2537
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.21037/atm-20-2537</ArticleId>
            <ArticleId IdType="pmc">PMC7940937</ArticleId>
            <ArticleId IdType="pubmed">33708880</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Blaauboer SM, Mansouri S, Tucker HR, Wang HL, Gabrielle VD, Jin L. The Mucosal Adjuvant Cyclic Di-GMP Enhances Antigen Uptake and Selectively Activates Pinocytosis-Efficient Cells In Vivo. Elife (2015) 4:e06670. doi: 10.7554/eLife.06670
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7554/eLife.06670</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Li L, Yin Q, Kuss P, Maliga Z, Millán JL, Wu H, et al. . Hydrolysis of 2’3’-cGAMP by ENPP1 and Design of Nonhydrolyzable Analogs. Nat Chem Biol (2014) 10:1043–8. doi: 10.1038/nchembio.1661
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nchembio.1661</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ding C, Song Z, Shen A, Chen T, Zhang A. Small Molecules Targeting the Innate Immune cGAS−STING−TBK1 Signaling Pathway. Acta Pharm Sin B (2020) 10:2272–98. doi: 10.1016/j.apsb.2020.03.001
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.apsb.2020.03.001</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ross PJ, Sutton CE, Higgins S, Allen AC, Walsh K, Misiak A, et al. . Relative Contribution of Th1 and Th17 Cells in Adaptive Immunity to Bordetella Pertussis: Towards the Rational Design of an Improved Acellular Pertussis Vaccine. PloS Pathog (2013) 9:e1003264. doi: 10.1371/journal.ppat.1003264
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.ppat.1003264</ArticleId>
            <ArticleId IdType="pmc">PMC3617212</ArticleId>
            <ArticleId IdType="pubmed">23592988</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kapil P, Merkel TJ. Pertussis Vaccines and Protective Immunity. Curr Opin Immunol (2019) 59:72–8. doi: 10.1016/j.coi.2019.03.006
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.coi.2019.03.006</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Misiak A, Leuzzi R, Allen AC, Galletti B, Baudner BC, D’Oro U, et al. . Addition of a TLR7 Agonist to an Acellular Pertussis Vaccine Enhances Th1 and Th17 Responses and Protective Immunity in a Mouse Model. Vaccine (2017) 35:5256–63. doi: 10.1016/j.vaccine.2017.08.009
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.vaccine.2017.08.009</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Solans L, Debrie AS, Borkner L, Aguiló N, Thiriard A, Coutte L, et al. . IL-17-Dependent SIgA-Mediated Protection Against Nasal Bordetella Pertussis Infection by Live Attenuated BPZE1 Vaccine. Mucosal Immunol (2018) 11:1753–62. doi: 10.1038/s41385-018-0073-9
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41385-018-0073-9</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Tuomanen EI, Zapiain LA, Galvan P, Hewlett EL. Characterization of Antibody Inhibiting Adherence of Bordetella Pertussis to Human Respiratory Epithelial Cells. J Clin Microbiol (1984) 20:167–70. doi: 10.1128/jcm.20.2.167-170.1984
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/jcm.20.2.167-170.1984</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Borkner L, Curham LM, Wilk MM, Moran B, Mills KHG. IL-17 Mediates Protective Immunity Against Nasal Infection With Bordetella Pertussis by Mobilizing Neutrophils, Especially Siglec-F(+) Neutrophils. Mucosal Immunol (2021) 14:1183–202. doi: 10.1038/s41385-021-00407-5
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41385-021-00407-5</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Mills KH, Barnard A, Watkins J, Redhead K. Cell-Mediated Immunity to Bordetella Pertussis: Role of Th1 Cells in Bacterial Clearance in a Murine Respiratory Infection Model. Infect Immun (1993) 61:399–410. doi: 10.1128/iai.61.2.399-410.1993
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/iai.61.2.399-410.1993</ArticleId>
            <ArticleId IdType="pmc">PMC302743</ArticleId>
            <ArticleId IdType="pubmed">8423070</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Redhead K, Watkins J, Barnard A, Mills KH. Effective Immunization Against Bordetella Pertussis Respiratory Infection in Mice is Dependent on Induction of Cell-Mediated Immunity. Infect Immun (1993) 61:3190–8. doi: 10.1128/iai.61.8.3190-3198.1993
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/iai.61.8.3190-3198.1993</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ryan M, Murphy G, Gothefors L, Nilsson L, Storsaeter J, Mills KH. Bordetella Pertussis Respiratory Infection in Children is Associated With Preferential Activation of Type 1 T Helper Cells. J Infect Dis (1997) 175:1246–50. doi: 10.1086/593682
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1086/593682</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Mascart F, Verscheure V, Malfroot A, Hainaut M, Piérard D, Temerman S, et al. . Bordetella Pertussis Infection in 2-Month-Old Infants Promotes Type 1 T Cell Responses. J Immunol (2003) 170:1504–9. doi: 10.4049/jimmunol.170.3.1504
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.170.3.1504</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Mahon BP, Sheahan BJ, Griffin F, Murphy G, Mills KH. Atypical Disease After Bordetella Pertussis Respiratory Infection of Mice With Targeted Disruptions of Interferon-Gamma Receptor or Immunoglobulin Mu Chain Genes. J Exp Med (1997) 186:1843–51. doi: 10.1084/jem.186.11.1843
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1084/jem.186.11.1843</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Geurtsen J, Fransen F, Vandebriel RJ, Gremmer ER, de la Fonteyne-Blankestijn LJ, Kuipers B, et al. . Supplementation of Whole-Cell Pertussis Vaccines With Lipopolysaccharide Analogs: Modification of Vaccine-Induced Immune Responses. Vaccine (2008) 26:899–906. doi: 10.1016/j.vaccine.2007.12.012
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.vaccine.2007.12.012</ArticleId>
            <ArticleId IdType="pubmed">18207288</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Li P, Asokanathan C, Liu F, Khaing KK, Kmiec D, Wei X, et al. . PLGA Nano/Micro Particles Encapsulated With Pertussis Toxoid (PTd) Enhances Th1/Th17 Immune Response in a Murine Model. Int J Pharm (2016) 513:183–90. doi: 10.1016/j.ijpharm.2016.08.059
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ijpharm.2016.08.059</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Holubová J, Staněk O, Brázdilová L, Mašín J, Bumba L, Gorringe AR, et al. . Acellular Pertussis Vaccine Inhibits Bordetella Pertussis Clearance From the Nasal Mucosa of Mice. Vaccines (Basel) (2020) 8:695. doi: 10.3390/vaccines8040695
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/vaccines8040695</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Verhoef PA, Constantinides MG, McDonald BD, Urban JF, Jr., Sperling AI, Bendelac A. Intrinsic Functional Defects of Type 2 Innate Lymphoid Cells Impair Innate Allergic Inflammation in Promyelocytic Leukemia Zinc Finger (PLZF)-Deficient Mice. J Allergy Clin Immunol (2016) 137:591–600.e1. doi: 10.1016/j.jaci.2015.07.050
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jaci.2015.07.050</ArticleId>
            <ArticleId IdType="pmc">PMC4747811</ArticleId>
            <ArticleId IdType="pubmed">26602165</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Du Y, Tu L, Zhu P, Mu M, Wang R, Yang P, et al. . Clinical Features of 85 Fatal Cases of COVID-19 From Wuhan. A Retrospective Observational Study. Am J Respir Crit Care Med (2020) 201:1372–9. doi: 10.1164/rccm.202003-0543OC
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1164/rccm.202003-0543OC</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. . Clinical Course and Risk Factors for Mortality of Adult Inpatients With COVID-19 in Wuhan, China: A Retrospective Cohort Study. Lancet (2020) 395:1054–62. doi: 10.1016/s0140-6736(20)30566-3
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/s0140-6736(20)30566-3</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Linch SN, Kelly AM, Danielson ET, Pero R, Lee JJ, Gold JA. Mouse Eosinophils Possess Potent Antibacterial Properties In Vivo. Infect Immun (2009) 77:4976–82. doi: 10.1128/iai.00306-09
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/iai.00306-09</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Krishack PA, Hollinger MK, Kuzel TG, Decker TS, Louviere TJ, Hrusch CL, et al. . IL-33-Mediated Eosinophilia Protects Against Acute Lung Injury. Am J Respir Cell Mol Biol (2021) 64:569–78. doi: 10.1165/rcmb.2020-0166OC
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1165/rcmb.2020-0166OC</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Dubois V, Chatagnon J, Thiriard A, Bauderlique-Le RH, Debrie AS, Coutte L, et al. . Suppression of Mucosal Th17 Memory Responses by Acellular Pertussis Vaccines Enhances Nasal Bordetella Pertussis Carriage. NPJ Vaccines (2021) 6:6. doi: 10.1038/s41541-020-00270-8
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41541-020-00270-8</ArticleId>
            <ArticleId IdType="pmc">PMC7794405</ArticleId>
            <ArticleId IdType="pubmed">33420041</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
